Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Jacot

Showing results (71-80 of 212) with videos related to

Pageof 22
Sort By:
Breast Cancer Research and Treatment|March 25, 2025
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort studyShanu Modi, Suyuan Zhang, Danalyn Byng, et al.
Cancer Reports (Hoboken, N.J.)|October 27, 2022
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility studyMichel Fabbro, William Jacot, Marta Jarlier, et al.
International Journal of Cancer|July 28, 2016
Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?Amélie Darlix, Pierre-Jean Lamy, Evelyne Lopez-Crapez, et al.
American Journal of Clinical Oncology|January 1, 2010
Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancerWilliam Jacot, Frédéric Bibeau, Sophie Gourgou-Bourgade, et al.
Cancer Management and Research|December 19, 2019
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?Marie Alexandre, Aurélie Maran-Gonzalez, Marie Viala, et al.
BMC Cancer|November 22, 2025
Hepcidin as an emerging predictor biomarker of leptomeningeal metastases in patients with metastatic breast cancerConstance Delaby, Anas Al Herk, Christophe Hirtz, et al.
BMC Cancer|July 9, 2016
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patientsAmélie Darlix, Pierre-Jean Lamy, Evelyne Lopez-Crapez, et al.
Cancers|March 6, 2021
Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast CancerFlorence Boissière-Michot, Ghita Chabab, Caroline Mollevi, et al.
Annals of Surgical Oncology|July 17, 2015
Oncoplastic Resection of Breast Cancers Located in the Lower-Inner or Lower-Outer Quadrant with the Modified McKissock Mammaplasty TechniquePierre-Emmanuel Colombo, Marine Lefèvre, Laure Delmond, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomesWilliam Jacot, Ludovic Lhermitte, Nadège Dossat, et al.
Pageof 22

Showing results (71-80 of 212) with videos related to

Sort By:
Pageof 22
Breast Cancer Research and Treatment|March 25, 2025
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort studyShanu Modi, Suyuan Zhang, Danalyn Byng, et al.
Cancer Reports (Hoboken, N.J.)|October 27, 2022
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility studyMichel Fabbro, William Jacot, Marta Jarlier, et al.
International Journal of Cancer|July 28, 2016
Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?Amélie Darlix, Pierre-Jean Lamy, Evelyne Lopez-Crapez, et al.
American Journal of Clinical Oncology|January 1, 2010
Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancerWilliam Jacot, Frédéric Bibeau, Sophie Gourgou-Bourgade, et al.
Cancer Management and Research|December 19, 2019
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?Marie Alexandre, Aurélie Maran-Gonzalez, Marie Viala, et al.
BMC Cancer|November 22, 2025
Hepcidin as an emerging predictor biomarker of leptomeningeal metastases in patients with metastatic breast cancerConstance Delaby, Anas Al Herk, Christophe Hirtz, et al.
BMC Cancer|July 9, 2016
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patientsAmélie Darlix, Pierre-Jean Lamy, Evelyne Lopez-Crapez, et al.
Cancers|March 6, 2021
Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast CancerFlorence Boissière-Michot, Ghita Chabab, Caroline Mollevi, et al.
Annals of Surgical Oncology|July 17, 2015
Oncoplastic Resection of Breast Cancers Located in the Lower-Inner or Lower-Outer Quadrant with the Modified McKissock Mammaplasty TechniquePierre-Emmanuel Colombo, Marine Lefèvre, Laure Delmond, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomesWilliam Jacot, Ludovic Lhermitte, Nadège Dossat, et al.
Pageof 22